Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. AAPL
6. ONON
7. AZN
8. TRMD
9. NVDA
10. RARE

Go back to Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
(NASDAQ: ARVN) Delayed: 8.29 -0.02 (0.24%)
Previous Close $8.31    52 Week High $ 
Open $8.29    52 Week Low $ 
Day High $8.35    P/E N/A 
Day Low $8.19    EPS $ 
Volume 95,709       

Pfizer Inc. (NYSE: PFE) Delayed: 27.39 -0.25 (0.9%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.66    P/E 16.60 
Day Low $27.34    EPS $1.65 
Volume 7,469,115       

Pfizer Inc. (NYSE: PFE) Delayed: 27.39 -0.25 (0.9%)
Previous Close $27.64    52 Week High $37.39 
Open $27.64    52 Week Low $28.25 
Day High $27.66    P/E 16.60 
Day Low $27.34    EPS $1.65 
Volume 7,469,115